Another is market opportunism, which was the case with Shkreli's increase of Daraprim and Mylan's increases on the EpiPen, Carrier said. "With these examples, it's less the fact that you have the consolidation and more the fact that they are just trying to take advantage of opportunity that they think they can get away with," he said.